Here, we describe a patient who developed secondary FSGS necessitating discontinuation of treatment at first but who was subsequently rechallenged with anti-VEGF-targeted treatment without recurrence of proteinuria. The gene discussed is VEGFA; the disease is focal segmental glomerulosclerosis.